Why The U.S. Remains The Most Expensive Market For 'Biologic' Drugs In The World
Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.
Read more on NPR
Health Care - December 20, 2018 at 01:02AM - Why The U.S. Remains The Most Expensive Market For 'Biologic' Drugs In The World
Không có nhận xét nào:
Đăng nhận xét